Abstract
Lipophilicities of seven structurally diverse angiotensin-converting enzyme (ACE) inhibitors, viz., captopril, zofenoprilat, enalaprilat, ramiprilat, lisinopril, fosinoprilat, and ceronapril (SQ29852), were compared by determining their octanol-water distribution coefficients (D) under physiological pH conditions. The distribution coefficients of zofenopril, enalapril, ramipril and fosinopril, which are the prodrug forms of zofenoprilat, enalaprilat, ramiprilat, and fosinoprilat, respectively, were also determined. Attempts were made to correlate lipophilicities with the reported data for oral absorption, protein binding, ACE inhibitory activity, propensity for biliary excretion, and penetration across the blood-brain barrier for these therapeutic entities. Better absorption of prodrugs compared to their respective active forms is in agreement with their greater lipophilicities. Captopril, lisinopril, and ceronapril are orally well absorbed despite their low lipophilicities, suggesting involvement of other factors such as a carrier-mediated transport process. Of all the compounds studied, the two most lipophilic ACE inhibitors, fosinoprilat and zofenoprilat, exhibit a rank-order correlation with respect to biliary excretion. This may explain the dual routes of elimination (renal and hepatic) observed with fosinoprilat in humans. The more lipophilic compounds also exhibit higher protein binding. Both the lipophilicity and a carrier-mediated process may be involved in penetration of some of these drugs into brain. For structurally similar compounds, in vitro ACE inhibitory activity increased with the increase in lipophilicity. However, no clear correlation between lipophilicity and ACE inhibitory activity emerged when different types of inhibitors are compared, possibly because their interactions with enzymes are primarily ionic in nature.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
M. A. Ondetti, B. Rubin, and D. W. Cushman. Design of specific inhibitors of angiotensin converting enzyme: New class of orally active antihypertensive agents. Science 196:441–444 (1977).
J. B. Kostis and E. A. DeFelice. New ACE inhibitors. In J. B. Kostis and E. A. DeFelice (eds.), Angiotensin Converting Enzyme Inhibitors Alan R. Liss, New York, 1987, pp. 213–261.
M. J. Wyvratt and A. A. Patchett. Recent developments in the design of angiotensin-converting enzyme inhibitors. Med. Res. Rev. 5:483–531 (1985).
D. W. Cushman, F. L. Wang, W. C. Fung, C. M. Harvey, and J. M. DeForrest. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. A.J.H. 2:294–306 (1989).
B. Costall, Z. P. Horovitz, M. E. Kelly, R. J. Naylor, and B. M. Tomkins. Influence of captopril and SQ29852 on basal learning and scopolamine impairment in aged mice. Presented at the International Symposium on ACE Inhibition, London, Feb. 14–17, 1989, Abstr. F163.
D. W. Cushman, M. A. Ondetti, E. M. Gordon, S. Natarajan, D. S. Karanewsky, J. Krapcho, and E. W. Petrillo. Rational design and biochemical utility of specific inhibitors of angiotensin-converting enzyme. J. Cardiovasc. Pharmacol. 10(Suppl.):S17–S30 (1987).
M. A. Ondetti. Structural relationships of angiotensin converting enzyme inhibitors to pharmacologic activity. Circulation 77(Suppl. I):74–78 (1988).
J. K. Seydel, D. Trettin, H. P. Cordes, O. Wasserman, and M. Malyusz. Quantitative structure-pharmacokinetic relationships derived on antibacterial sulfonamides in rats and its comparison to quantitative structure-activity relationships. J. Med. Chem. 23:607–613 (1980).
C. Hansch and E. J. Ariens (ed.). In Drug Design, Vol. I Academic Press, New York, 1971, pp. 271–342.
C. Hansch, J. P. Bjorkroth, and A. Leo. Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 76:663–687 (1987).
P. Gohlke, H. Urbach, B. Scholkens, and T. Unger. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors. J. Pharmacol. Exp. Ther. 249:609–616 (1989).
O. H. Drummer, J. Nicolaci, and D. Iakovidis. Biliary excretion and conjugation of diacid angiotensin-converting enzyme inhibitors. J. Pharmacol. Exp. Ther. 252:1202–1206 (1990).
R. D. Carr, A. E. Cooper, R. Hutchinson, J. Mann, S. E. O'Connor, D. H. Robinson, and E. Wells. Preferential biliary elimination of FPL63547, a novel inhibitor of angiotensin converting enzyme, in the rat. Br. J. Pharmacol. 100:90–94 (1990).
A. Leo, C. Hansch, and D. Elkins. Partition coefficients and their uses. Chem. Rev. 71:525–616 (1971).
D. D. Perrin. Prediction of pKa values. In S. H. Yalkowsky, A. A. Sinkula, and S. C. Valvani (eds.), Physical Chemical Properties of Drugs Marcel Dekker, New York, 1980, pp. 1–48.
A. T. M. Serajuddin, S. A. Ranadive, D. L. Ballesteros, A. B. Thakur, and D. A. Wadke. Effect of electrolytes on solubility and partition coefficient of fosinopril sodium. Pharm. Res. 6(Suppl.):138(S) (1989).
S. H. Kubo and R. J. Cody. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors, a review. Clin. Pharmacokin. 10:377–391 (1985).
S. A. Singhvi, J. E. Foley, D. A. Willard, and R. A. Morrison. Disposition of zofenopril calcium in healthy subjects. J. Pharm. Sci. 79:970–973 (1990).
J. H. Lin, I. Chen, E. H. Ulm, and D. E. Duggan. Differential renal-handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. Drug Me tab. Disp. 16:392–396 (1988).
E. H. Ulm. Enalapril maleate (MK-421), a potent, nonsulfhydryl agiotensin converting enzyme inhibitor: Absorption, disposition, and metabolism in man. Drug Metab. Rev. 14:99–110 (1983).
H. G. Eckert, M. J. Badian, D. Gantz, H. M. Kellner, and M. Volz. Pharmacokinetics and biotransformation of 2-[N-[(S)-l-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(lS,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Arzneim. Forsch. 34:1435–1447 (1984).
S. G. Lancaster and P. A. Todd. Lisinopril: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 35:646–669 (1988).
S. M. Singhvi, K. L. Duchin, R. A. Morrison, D. A. Willard, D. W. Everett, and M. Frantz. Disposition of fosinopril sodium in healthy subjects. Br. J. Clin. Pharmacol. 25:9–15 (1988).
J. Foley, R. Morrison, S. Singhvi, J. Manning, and D. Willard. Pharmacokinetics and pharmacodynamics of SQ29852, a new metabolically stable phosphorus-containing angiotensin-converting enzyme (ACE) inhibitor. Pharmacologist 30:A156 (Abstract No. 109.1) (1988).
D. I. Friedman and G. L. Amidon. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm. Res. 6:1043–1047 (1989).
M. Hu and G. L. Amidon. Passive and carrier-mediated intestinal absorption components of captopril. J. Pharm. Sci. 77:1007–1011 (1988).
D. I. Friedman and G. L. Amidon. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm. Res. 5:104 (1988).
K. K. Hui, K. L. Duchin, K. J. Kripalini, D. Chan, P. K. Kramer, and N. Yanagawa. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin. Pharmacol Ther. 49:457–467 (1991).
W. H. Oldendorf. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol. 221:1629–1639 (1971).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ranadive, S.A., Chen, A.X. & Serajuddin, A.T.M. Relative Lipophilicities and Structural-Pharmacological Considerations of Various Angiotensin-Converting Enzyme (ACE) Inhibitors. Pharm Res 9, 1480–1486 (1992). https://doi.org/10.1023/A:1015823315983
Issue Date:
DOI: https://doi.org/10.1023/A:1015823315983